Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases. Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. Additionally, the company engages in the technology development, transfer, consulting, and promotion activities. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. was founded in 1996 and is based in Shanghai, the People's Republic of China.
Metrics to compare | 688505 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688505PeersSector | |
---|---|---|---|---|
P/E Ratio | 222.5x | 31.2x | −0.5x | |
PEG Ratio | −3.66 | −1.04 | 0.00 | |
Price/Book | 3.9x | 3.1x | 2.6x | |
Price / LTM Sales | 12.0x | 3.4x | 3.3x | |
Upside (Analyst Target) | - | 13.5% | 42.4% | |
Fair Value Upside | Unlock | 10.1% | 7.2% | Unlock |